Endonovo Therapeutics Inc (ENDV) 0.1350 $ENDV
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome
Marketwire Canada - Wed Jun 29, 8:32AM CDT
LOS ANGELES, CA--(Marketwired - Jun 29, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic.
Biotech Hot This Summer
ACCESSWIRE - Mon Jun 27, 10:39AM CDT
LAS VEGAS, NY / ACCESSWIRE / June 27, 2016 / A few biotech companies could be set to heat up now that the summer is officially here.
TLOG: 0.30 (-0.01)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
SeeThruEquity Initiates Coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a Price Target Price of $1.15
ACCESSWIRE - Wed May 25, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 25, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a price target of $1.15.
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 0.66 (+0.04)
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Marketwired - Thu May 05, 1:47PM CDT
LOS ANGELES, CA--(Marketwired - May 5, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central.
Biotech Quietly Preparing Technical Breakouts
ACCESSWIRE - Mon Apr 18, 8:17AM CDT
LA VEGAS, NV / ACCESSWIRE / April 18, 2016 / Both pharmaceutical and biotech stocks had a rough year but technical indicators suggest that perhaps the bear market on these sectors is over. One company we are very bullish on is Endonovo Therapeutics, Inc. (ENDV).
IBB: 260.08 (-2.67), PTCT: 6.83 (-0.32)
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Marketwired - Wed Apr 13, 7:34AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.
Six Technologies That Will Change Healthcare
ACCESSWIRE - Thu Apr 07, 8:32AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Here are 6 technologies that will change the face of the global healthcare market in the next 5 years.
CARA: 4.93 (-0.18)
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Marketwired - Wed Mar 30, 2:12PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.10 (-0.25), CMRX: 3.84 (-0.22), GERN: 2.67 (-0.08), CYTX: 2.04 (-0.05), CLDX: 4.52 (-0.07), SGMO: 5.96 (-0.06), PTCT: 6.83 (-0.32), ATHX: 2.28 (+0.06), MNKD: 1.12 (-0.06)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs.
CPXX: 30.20 (-0.02), DNAI: 1.94 (-0.09)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT", is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space.
CSII: 18.47 (-0.59), TROV: 4.47 (-0.07)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.20 (-0.02), INO: 9.17 (-0.18), CMRX: 3.84 (-0.22), ORPN: 1.70 (+0.01), BLRX: 0.81 (unch)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.10 (-0.25), VCEL: 2.17 (-0.09), SGMO: 5.96 (-0.06), ZYNE: 7.00 (+0.07)
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook
Marketwired - Mon Mar 14, 2:10PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today a number of corporate developments.
Hidden Market Patterns, History Repeats Itself - Analyst Notes on Viropro, Baristas Coffee Company, Endonovo Therapeutics and Bayerische Motoren Werke
ACCESSWIRE - Mon Mar 14, 6:55AM CDT
NEW YORK, NY / ACCESSWIRE / March 14, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Viropro Inc. (OTC: VPRO), Baristas Coffee Company Inc. (OTC: BCCID), Endonovo Therapeutics Inc. (OTC: ENDV) and Bayerische Motoren Werke AG (OTC: BAMXY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
The Biotech Bull Market Is Back
ACCESSWIRE - Wed Mar 09, 8:43AM CST
LAS VEGAS, NV / ACCESSWIRE / March 9, 2016 / In 2012 the NYSE Biotechnology Index began a climb, this bull market went nearly unimpeded from $1000 a share in 2012 to nearly $4400 a share by July of 2015. That's when biotech as a part of the larger indexes began to make a bearish turn, then in February the market began to make a recovery. The NYSE Biotechnology Index in particular has bounced hard off of a long term uptrend line.
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome
Marketwire Canada - Wed Jun 29, 8:32AM CDT
LOS ANGELES, CA--(Marketwired - Jun 29, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic. Biotech Hot This Summer
ACCESSWIRE - Mon Jun 27, 10:39AM CDT
LAS VEGAS, NY / ACCESSWIRE / June 27, 2016 / A few biotech companies could be set to heat up now that the summer is officially here.
TLOG: 0.30 (-0.01)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
SeeThruEquity Initiates Coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a Price Target Price of $1.15
ACCESSWIRE - Wed May 25, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 25, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a price target of $1.15.
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 0.66 (+0.04)
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Marketwired - Thu May 05, 1:47PM CDT
LOS ANGELES, CA--(Marketwired - May 5, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central. Biotech Quietly Preparing Technical Breakouts
ACCESSWIRE - Mon Apr 18, 8:17AM CDT
LA VEGAS, NV / ACCESSWIRE / April 18, 2016 / Both pharmaceutical and biotech stocks had a rough year but technical indicators suggest that perhaps the bear market on these sectors is over. One company we are very bullish on is Endonovo Therapeutics, Inc. (ENDV).
IBB: 260.08 (-2.67), PTCT: 6.83 (-0.32)
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Marketwired - Wed Apr 13, 7:34AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City. Six Technologies That Will Change Healthcare
ACCESSWIRE - Thu Apr 07, 8:32AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Here are 6 technologies that will change the face of the global healthcare market in the next 5 years.
CARA: 4.93 (-0.18)
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Marketwired - Wed Mar 30, 2:12PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.10 (-0.25), CMRX: 3.84 (-0.22), GERN: 2.67 (-0.08), CYTX: 2.04 (-0.05), CLDX: 4.52 (-0.07), SGMO: 5.96 (-0.06), PTCT: 6.83 (-0.32), ATHX: 2.28 (+0.06), MNKD: 1.12 (-0.06)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs. CPXX: 30.20 (-0.02), DNAI: 1.94 (-0.09)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT"
, is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space. CSII: 18.47 (-0.59), TROV: 4.47 (-0.07)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.20 (-0.02), INO: 9.17 (-0.18), CMRX: 3.84 (-0.22), ORPN: 1.70 (+0.01), BLRX: 0.81 (unch)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.10 (-0.25), VCEL: 2.17 (-0.09), SGMO: 5.96 (-0.06), ZYNE: 7.00 (+0.07)
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook
Marketwired - Mon Mar 14, 2:10PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today a number of corporate developments. Hidden Market Patterns, History Repeats Itself - Analyst Notes on Viropro, Baristas Coffee Company, Endonovo Therapeutics and Bayerische Motoren Werke
ACCESSWIRE - Mon Mar 14, 6:55AM CDT
NEW YORK, NY / ACCESSWIRE / March 14, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Viropro Inc. (OTC: VPRO), Baristas Coffee Company Inc. (OTC: BCCID), Endonovo Therapeutics Inc. (OTC: ENDV) and Bayerische Motoren Werke AG (OTC: BAMXY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
The Biotech Bull Market Is Back
ACCESSWIRE - Wed Mar 09, 8:43AM CST
LAS VEGAS, NV / ACCESSWIRE / March 9, 2016 / In 2012 the NYSE Biotechnology Index began a climb, this bull market went nearly unimpeded from $1000 a share in 2012 to nearly $4400 a share by July of 2015. That's when biotech as a part of the larger indexes began to make a bearish turn, then in February the market began to make a recovery. The NYSE Biotechnology Index in particular has bounced hard off of a long term uptrend line.
